title: Receptor-mediated release of inositol 1,4,5-trisphosphate and inositol 1,4-bisphosphate in rat basophilic leukemia RBL-2H3 cells permeabilized with streptolysin O.
abstract: Antigen-mediated exocytosis in intact rat basophilic leukemia (RBL-2H3) cells is associated with substantial hydrolysis of membrane inositol phospholipids and an elevation in concentration of cytosol Ca2+ ([ Ca2+i]). Paradoxically, these two responses are largely dependent on external Ca2+. We report here that cells labeled with myo-[3H]inositol and permeabilized with streptolysin O do release [3H]inositol 1,4,5-trisphosphate upon stimulation with antigen or guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) at low (less than 100 nM) concentrations of free Ca2+. The response, however, is amplified by increasing free Ca2+ to 1 microM. The subsequent conversion of the trisphosphate to inositol 1,3,4,5-tetrakisphosphate is enhanced also by the increase in free Ca2+. Although [3H]inositol 1,4,5-trisphosphate accumulates in greater amounts than is the case in intact cells, [3H]inositol 1,4-bisphosphate is still the major product in permeabilized cells even when the further metabolism of [3H]inositol 1,4,5-trisphosphate is suppressed (by 77%) by the addition of excess (1000 microM) unlabeled inositol 1,4,5-trisphosphate and the phosphatase inhibitor 2,3-bisphosphoglycerate. It would appear that either the activity of the membrane 5-phosphomonoesterase allows virtually instantaneous dephosphorylation of the inositol 1,4,5-trisphosphate under all conditions tested or both phosphatidylinositol 4-monophosphate and the 4,5-bisphosphate are substrates for the activated phospholipase C. The latter alternative is supported by the finding that permeabilized cells, which respond much more vigorously to high (supraoptimal) concentrations of antigen than do intact RBL-2H3 cells, produce substantial amounts of [3H]inositol 1,4-bisphosphate before any detectable increase in levels of [3H]inositol 1,4,5-trisphosphate.
authors.affiliation: Laboratory of Chemical Pharmacology, National Heart, Lung, and Blood Inst., Bethesda, MD 20892.
authors.forename: H
authors.initials: H
authors.lastname: Ali
authors.forename: J R
authors.initials: JR
authors.lastname: Cunha-Melo
authors.forename: M A
authors.initials: MA
authors.lastname: Beaven
mesh_terms: D000818:Animals; D001426:Bacterial Proteins; D002460:Cell Line; D005089:Exocytosis; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D006160:Guanosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D015544:Inositol 1,4,5-Trisphosphate; D007295:Inositol Phosphates / Q000378:metabolism*; D015471:Leukemia, Basophilic, Acute / Q000378:metabolism*; D051381:Rats; D013301:Streptolysins / Q000494:pharmacology*; D013403:Sugar Phosphates / Q000378:metabolism*; D013873:Thionucleotides / Q000494:pharmacology
chemical_list: D001426:Bacterial Proteins; D007295:Inositol Phosphates; D013301:Streptolysins; D013403:Sugar Phosphates; D013873:Thionucleotides; C025964:streptolysin O; D016244:Guanosine 5'-O-(3-Thiotriphosphate); C044259:inositol 1,4-bis(phosphate); D015544:Inositol 1,4,5-Trisphosphate; D006160:Guanosine Triphosphate